{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T03:00:54Z","timestamp":1777086054883,"version":"3.51.4"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,7,3]]},"DOI":"10.7759\/cureus.16147","type":"journal-article","created":{"date-parts":[[2021,7,3]],"date-time":"2021-07-03T18:44:00Z","timestamp":1625337840000},"source":"Crossref","is-referenced-by-count":2,"title":["New-Onset Collagenous Colitis in a Patient With Psoriatic Arthritis: Can It Be Secukinumab?"],"prefix":"10.7759","author":[{"given":"Adham E","family":"Obeidat","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Traci T","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1080\/00365520510011623","article-title":"Collagenous colitis and lymphocytic colitis: patient characteristics and clinical presentation","volume":"40","author":"Chande N","year":"2005","unstructured":"Chande N, Driman DK, Reynolds RP. Collagenous colitis and lymphocytic colitis: patient characteristics and clinical presentation. Scand J Gastroenterol. 2005, 40:343-7. 10.1080\/00365520510011623","journal-title":"Scand J Gastroenterol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.5858\/2010-0295-CR.1","article-title":"The collagenous gastroenteritides: similarities and differences","volume":"134","author":"Gopal P","year":"2010","unstructured":"Gopal P, McKenna BJ. The collagenous gastroenteritides: similarities and differences. Arch Pathol Lab Med. 2010, 134:1485-9. 10.5858\/2010-0295-CR.1","journal-title":"Arch Pathol Lab Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.100573","article-title":"NSAID-induced collagenous colitis","volume":"37","author":"Milman N","year":"2010","unstructured":"Milman N, Kraag G. NSAID-induced collagenous colitis. J Rheumatol. 2010, 37:2432-3. 10.3899\/jrheum.100573","journal-title":"J Rheumatol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2008.02.005","article-title":"Coexistence of psoriatic arthritis and collagenous colitis with inflammatory nervous system disease","volume":"75","author":"Azzouz D","year":"2008","unstructured":"Azzouz D, Gargouri A, Hamdi W, et al.. Coexistence of psoriatic arthritis and collagenous colitis with inflammatory nervous system disease. Joint Bone Spine. 2008, 75:624-5. 10.1016\/j.jbspin.2008.02.005","journal-title":"Joint Bone Spine"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/620241","article-title":"Collagenous colitis and spondylarthropathy","volume":"2012","author":"Ben Abdelghani K","year":"2012","unstructured":"Ben Abdelghani K, Sahli H, Souabni L, et al.. Collagenous colitis and spondylarthropathy. Case Rep Med. 2012, 2012:620241. 10.1155\/2012\/620241","journal-title":"Case Rep Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/9679287","article-title":"A challenging case of severe ulcerative colitis following the initiation of secukinumab for ankylosing spondylitis","volume":"2018","author":"Ehrlich D","year":"2018","unstructured":"Ehrlich D, Jamaluddin N, Pisegna J, Padua D. A challenging case of severe ulcerative colitis following the initiation of secukinumab for ankylosing spondylitis. Case Rep Gastrointest Med. 2018, 2018:9679287. 10.1155\/2018\/9679287","journal-title":"Case Rep Gastrointest Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2011-301668","article-title":"Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial","volume":"61","author":"Hueber W","year":"2012","unstructured":"Hueber W, Sands BE, Lewitzky S, et al.. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut. 2012, 61:1693-700. 10.1136\/gutjnl-2011-301668","journal-title":"Gut"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.17235\/reed.2019.5841\/2018","article-title":"The onset of ulcerative colitis during treatment with secukinumab: can anti-IL-17A be a trigger for inflammatory bowel disease?","volume":"111","author":"Rodr\u00edguez Moncada R","year":"2019","unstructured":"Rodr\u00edguez Moncada R, V\u00e1zquez Mor\u00f3n JM, Pallar\u00e9s Manrique H. The onset of ulcerative colitis during treatment with secukinumab: can anti-IL-17A be a trigger for inflammatory bowel disease?. Rev Esp Enferm Dig. 2019, 111:720-1. 10.17235\/reed.2019.5841\/2018","journal-title":"Rev Esp Enferm Dig"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3109\/03009748309102892","article-title":"Arthritis and collagenous colitis. Report of a case with concomitant chronic polyarthritis and collagenous colitis","volume":"12","author":"Erlendsson J","year":"1983","unstructured":"Erlendsson J, Fenger C, Meinicke J. Arthritis and collagenous colitis. Report of a case with concomitant chronic polyarthritis and collagenous colitis. Scand J Rheumatol. 1983, 12:93-5. 10.3109\/03009748309102892","journal-title":"Scand J Rheumatol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007\/s100670200088","article-title":"Co-occurrence of psoriatic arthritis with collagenous colitis: clinicopathologic findings of a case","volume":"21","author":"Taccari E","year":"2002","unstructured":"Taccari E, Spada S, Giuliani A, Riccieri V, Sorgi ML, Pecorella I, Onetti Muda A. Co-occurrence of psoriatic arthritis with collagenous colitis: clinicopathologic findings of a case. Clin Rheumatol. 2002, 21:335-8. 10.1007\/s100670200088","journal-title":"Clin Rheumatol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2005.02561.x","article-title":"Review article: drug-induced microscopic colitis - proposal for a scoring system and review of the literature","volume":"22","author":"Beaugerie L","year":"2005","unstructured":"Beaugerie L, Pardi DS. Review article: drug-induced microscopic colitis - proposal for a scoring system and review of the literature. Aliment Pharmacol Ther. 2005, 22:277-84. 10.1111\/j.1365-2036.2005.02561.x","journal-title":"Aliment Pharmacol Ther"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1111\/apt.13583","article-title":"High risk of drug-induced microscopic colitis with concomitant use of NSAIDs and proton pump inhibitors","volume":"43","author":"Verhaegh BP","year":"2016","unstructured":"Verhaegh BP, de Vries F, Masclee AA, et al.. High risk of drug-induced microscopic colitis with concomitant use of NSAIDs and proton pump inhibitors. Aliment Pharmacol Ther. 2016, 43:1004-13. 10.1111\/apt.13583","journal-title":"Aliment Pharmacol Ther"},{"key":"ref13","article-title":"Long-term effects of interleukin-17A inhibition with secukinumab in active ankylosing spondylitis: 3-year efficacy and safety results from an extension of the Phase 3 MEASURE 1 trial","volume":"36","author":"Baraliakos X","year":"2018","unstructured":"Baraliakos X, Kivitz AJ, Deodhar AA, et al.. Long-term effects of interleukin-17A inhibition with secukinumab in active ankylosing spondylitis: 3-year efficacy and safety results from an extension of the Phase 3 MEASURE 1 trial. Clin Exp Rheumatol. 2018, 36:50-5.","journal-title":"Clin Exp Rheumatol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1505066","article-title":"Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis","volume":"373","author":"Baeten D","year":"2015","unstructured":"Baeten D, Sieper J, Braun J, et al.. Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis. N Engl J Med. 2015, 373:2534-48. 10.1056\/NEJMoa1505066","journal-title":"N Engl J Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-214273","article-title":"Incidence rates of inflammatory bowel disease in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis treated with secukinumab: a retrospective analysis of pooled data from 21 clinical trials","volume":"78","author":"Schreiber S","year":"2019","unstructured":"Schreiber S, Colombel JF, Feagan BG, et al.. Incidence rates of inflammatory bowel disease in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis treated with secukinumab: a retrospective analysis of pooled data from 21 clinical trials. Ann Rheum Dis. 2019, 78:473-9. 10.1136\/annrheumdis-2018-214273","journal-title":"Ann Rheum Dis"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-eular.3684","article-title":"OP0113 no increased incidence of inflammatory bowel disease among secukinumab-treated patients with moderate to severe psoriasis, psoriatic arthritis, or ankylosing spondylitis: data from 14 phase 2 and phase 3 clinical studies","volume":"75","author":"Schreiber S","year":"2016","unstructured":"Schreiber S, Sands B, Deodhar A, et al.. OP0113 no increased incidence of inflammatory bowel disease among secukinumab-treated patients with moderate to severe psoriasis, psoriatic arthritis, or ankylosing spondylitis: data from 14 phase 2 and phase 3 clinical studies. Ann Rheum Dis. 2016, 75:97.2-98. 10.1136\/annrheumdis-2016-eular.3684","journal-title":"Ann Rheum Dis"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2015.10.001","article-title":"Gut-busters: IL-17 ain't afraid of no IL-23","volume":"43","author":"Whibley N","year":"2015","unstructured":"Whibley N, Gaffen SL. Gut-busters: IL-17 ain't afraid of no IL-23. Immunity. 2015, 43:620-2. 10.1016\/j.immuni.2015.10.001","journal-title":"Immunity"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2019.102429","article-title":"Critical role of interleukin (IL)-17 in inflammatory and immune disorders: An updated review of the evidence focusing in controversies","volume":"19","author":"Ruiz de Morales JM","year":"2020","unstructured":"Ruiz de Morales JM, Puig L, Daud\u00e9n E, et al.. Critical role of interleukin (IL)-17 in inflammatory and immune disorders: An updated review of the evidence focusing in controversies. Autoimmun Rev. 2020, 19:102429. 10.1016\/j.autrev.2019.102429","journal-title":"Autoimmun Rev"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2003.09.013","article-title":"Neutralization of interleukin-17 aggravates dextran sulfate sodium-induced colitis in mice","volume":"110","author":"Ogawa A","year":"2004","unstructured":"Ogawa A, Andoh A, Araki Y, Bamba T, Fujiyama Y. Neutralization of interleukin-17 aggravates dextran sulfate sodium-induced colitis in mice. Clin Immunol. 2004, 110:55-62. 10.1016\/j.clim.2003.09.013","journal-title":"Clin Immunol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/62883-new-onset-collagenous-colitis-in-a-patient-with-psoriatic-arthritis-can-it-be-secukinumab","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:31:09Z","timestamp":1707507069000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/62883-new-onset-collagenous-colitis-in-a-patient-with-psoriatic-arthritis-can-it-be-secukinumab"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,3]]},"references-count":19,"URL":"https:\/\/doi.org\/10.7759\/cureus.16147","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7,3]]}}}